Multibagger stocks: BLS International, which has increased the money of investors in five years in five years, has also advised BLS International to buy brokerage firm Nuwama. The brokerage firm has also increased the target price. Due to this, the shares of BLS International, which provide visa service, jumped more than 4 per cent in Intra-Day today but still this is more than 25 per cent downside from record high. Today, it has closed at Rs 387.50 (BLS International Share Price) with a rise of 2.50 per cent on ENSE. It jumped 4.46 per cent to Rs 394.90 in intra-day.
What is the target price of investment in BLS International?
Before knowing the view of brokerage, BLS International business results are known. This company, formed in the year 2005, provides visas, passports, consular, e-governors, attesions, biometrics, e-visas and retail services. On the annual basis in the December quarter, the company’s net profit rose 43.2% to ₹ 121 crore on an annual basis. During this period, the company’s operational revenue jumped 17% to ₹ 513 crore and the operating profit rises 78.5% to ₹ 158.1 crore. The operating margin rose rapidly from 20.2% to 30.8% on the self-maintained approach and new business on the partner-operated model. In the end of December 2024, the company’s net cash balance was ₹ 690 crore.
Nuwama says the company’s performance remained as expected and it received a record revenue in the December quarter. Brokerage says it is the only listed company of visa processing and its business model is capital light and cash-generating. According to brokerage, expansion of new visa contracts and digital services networks may increase its profitability. The brokerage firm says that its track record of acquisition is quite strong and through this the company’s market is growing and the service portfolio is also increasing. In such a situation, the brokerage firm has retained its purchase rating and has increased the target price from ₹ 604 to ₹ 637.
How was the status of shares in a year?
BLS International shares had given more than 98 per cent returns in 10 months last year i.e. the money of investors almost doubled. Last year, on 13 March 2024 it was at Rs 262.95, which is a one year low for its shares. It rose more than 98 per cent in 10 months from this lower level to Rs 521.80 on 3 January 2025 last month, which is a record high for its shares. However, the shares came to a standstill here and currently it is more than 25 per cent downside from this record high.
Pharma Stocks Fall: 10% broken shares on tariff threats on medicines, but these pharma stocks are safe
Disclaimer: Advice or idea experts/brokerage firms on Moneycontrol.com have their own personal views. The website or management is not responsible for this. Moneycontrol advises to users that always seek the advice of certified experts before taking any investment decision.